奥拉西坦与多奈哌齐治疗老年血管性痴呆对照研究

A control study of oxiracetam vs donepezil in the treatment of senile vascular dementia

目的 评价奥拉西坦与多奈哌齐治疗老年血管性痴呆患者的临床疗效和安全性.方法 将60例老年血管性痴呆患者随机分为两组,每组30例,研究组口服奥拉西坦治疗,对照组口服多奈哌齐治疗,观察12周.于治疗前及治疗12周末,采用简易智力状态检查量表、韦氏记忆量表和临床疗效总评量表病情严重程度分量表评定临床疗效,同时记录治疗过程中出现的不良反应.结果 治疗后两组简易智力状态检查量表、韦氏记忆量表和临床疗效总评量表病情严重程度分量表评分均较治疗前有显著下降（P＜0.01）,同期两组间各量表评分比较差异均无显著性（P＞0.05）;研究期间两组各项检查均无明显异常改变,均未出现明显的不良反应.结论 奥拉西坦与多奈哌齐治疗均能显著改善血管性痴呆患者的智力状态和记忆力,临床疗效显著,安全性高,值得临床推广应用.

Objeetive To evaluate the efficacy and safety of oxiracetam vs donepezil in the treatment of senile patients with vascular dementia （VD）. Methods Sixty senile VD patients were randomly divided into two groups of 30 ones each, research group took orally oxiracetam and control group did donepezil for 12 weeks. Before treatment and at the end of the 12^th week, clinical efficacies were assessed with the Mini-Mental State Examination （MMSE）, Weehsler Memory Scale （WMS） and Clinical Global Impression Severity scale （CGI-S）, and adverse reactions simultaneously recorded during treatment. Results After treatment the MMSE, WMS and CGI-S score lowered more significantly compared with pretreatment （P〈0.01）, there were no significant differences in contemporaneous group comparisons of each scale score （P〈0.05） ; during research, all examinations of both groups had no notable abnormal changes and both groups did no apparent adverse reactions. Conclusion Both oxiraeetam and donepezil could notably improve intelligence state and ability of memory of VD patients, have evident effects and higher safety, and deserve clinical generalization and utilization.